Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already…
The global train collision avoidance system market is expected to reach $13.32 billion by 2030, growing at a compound annual…
Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy…
LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora…
The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary…
LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The…
Jack Dorsey is making a concrete bet that artificial intelligence can replace what middle managers have done in large organizations for generations.…
Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more…
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in…
Cancer patients with healthier thymus glands show dramatically better responses to immunotherapy, cutting progression risks by roughly one-third and death risks by nearly half compared…